HEK293 expression platform (L-10894/11266/11565) .: NR16-179/2017E-PDF
“There is an increasing demand for biopharmaceuticals such as vaccines, humanized monoclonal antibodies, and gene therapy products produced from animal cell culture processes. The NRC’s HEK293 expression system enables the high yield production of viral vector and post-translationally modified recombinant proteins through suspension-growing, serum-free adapted cell lines. It provides an optimized, chemically defined formulation for serum-free suspension culture of this cell line. The cell line can be used in combination with the cumate and coumermycin switches, which enable producers to turn on the expression of a given protein only when needed”--Highlights.
Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.847672&sl=0
| Department/Agency | National Research Council Canada. |
|---|---|
| Title | HEK293 expression platform (L-10894/11266/11565) . |
| Publication type | Monograph |
| Language | [English] |
| Other language editions | [French] |
| Format | Electronic |
| Electronic document | |
| Note(s) | Issued also in French under title: Plateforme d’expression HEK293 (L-10894/11266/11565). Caption title. "December 2017." Issued also in print format. |
| Publishing information | [Ottawa] : National Research Council Canada, [2018] |
| Description | [1] p. |
| ISBN | 9780660239897 |
| Catalogue number |
|
| Subject terms | Recombinant proteins Cultures and culture media HEK293 Cells |
Request alternate formats
To request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.- Date modified: